Product image of Nemluvio (Nemolizumab) supplied by GNH India

Nemluvio

Active Ingredient:
Nemolizumab
Origin:
EU

Nemluvio (Nemolizumab)

Nemolizumab, the active ingredient in Nemluvio, is a monoclonal antibody presented as a subcutaneous injection for subcutaneous use. It is designed to modulate immune pathways that contribute to chronic itch and skin inflammation in certain dermatologic conditions.
GNH India supplies Nemluvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Galderma International

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nemluvio targets the interleukin‑31 pathway, which is implicated in pruritic dermatologic disorders. It is clinically employed for the following indications:

  • Atopic dermatitis (moderate‑to‑severe): reduces itch intensity and improves skin lesions.
  • Prurigo nodularis: alleviates persistent nodular itching and promotes lesion resolution.
  • Chronic pruritus associated with other inflammatory skin diseases: provides itch relief when conventional therapies are insufficient.

How It Works

  • Nemolizumab binds with high affinity to the interleukin‑31 receptor A (IL‑31RA) on target cells, blocking IL‑31 mediated signaling. By inhibiting this cytokine pathway, the antibody reduces neuronal activation and inflammatory cascades that drive pruritus and skin inflammation, resulting in decreased itch sensation and improved dermatologic outcomes.

Side Effects

Nemluvio may be associated with a range of adverse reactions. The frequency and severity vary among patients.

Common Side Effects

  • Injection site pain or erythema.
  • Nasopharyngitis or upper respiratory tract infection.
  • Headache.
  • Fatigue.
  • Gastrointestinal discomfort.
  • Transient increase in eosinophil count.

Serious or Rare Side Effects

  • Anaphylactic or severe hypersensitivity reactions.
  • Serious infections, including opportunistic pathogens.
  • Neutropenia or other hematologic abnormalities.
  • Autoimmune phenomena such as lupus‑like syndrome.
  • Cardiovascular events (rare).

Precautions & Warnings

When prescribing Nemluvio, clinicians should consider several safety measures:

  • Infection risk: monitor patients for signs of infection and postpone treatment if active infection is present.
  • Hypersensitivity: assess history of allergic reactions to monoclonal antibodies before initiation.
  • Immunocompromised status: use with caution in patients receiving other immunosuppressive therapies.
  • Vaccination: avoid live vaccines during treatment and for several weeks after the last dose.
  • Pregnancy and lactation: discuss potential risks with women of childbearing potential; use only if benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Avoid Interactions

Nemluvio’s biologic nature warrants attention to concomitant therapies that may alter its safety or efficacy.

Major Interactions (Avoid)

  • Live vaccines: concurrent administration can lead to uncontrolled infection.
  • Known severe hypersensitivity to other monoclonal antibodies targeting IL‑31 pathways.

Moderate Interactions (Monitor Closely)

  • Other immunosuppressants (e.g., systemic corticosteroids, methotrexate): may increase infection susceptibility.
  • Antiviral or antifungal agents that affect immune function: monitor for additive immunosuppression.
  • Cytokine‑modulating agents: assess for overlapping adverse effect profiles.

Frequently Asked Questions

Nemluvio (nemolizumab) is indicated for moderate‑to‑severe atopic dermatitis and prurigo nodularis, as well as chronic pruritus linked to other inflammatory skin disorders. In these conditions it helps reduce intense itching and improves skin lesions when standard therapies are inadequate.

Nemolizumab is a monoclonal antibody that binds to the interleukin‑31 receptor A on skin and nerve cells. By blocking IL‑31 signaling, it interrupts the itch‑inducing and inflammatory pathways, leading to decreased pruritus and reduced skin inflammation.

The dosing regimen for Nemluvio is determined by the prescribing clinician based on the patient’s condition, weight, and response to therapy. Specific dose amounts and frequency are outlined in the product’s prescribing information and should be followed as directed by a qualified health professional.

Safety data for nemolizumab in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To request Nemluvio, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Nemluvio targets the IL‑31 pathway, a mechanism distinct from traditional systemic agents such as cyclosporine or newer biologics like dupilumab that block IL‑4/IL‑13. This specific inhibition can provide rapid itch relief, especially in patients whose symptoms are driven by IL‑31, offering an alternative when other therapies are insufficient.

Nemluvio should be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours before use.

Nemluvio is administered by subcutaneous injection, typically performed by a healthcare professional in a clinical setting. The injection is given into the abdomen or thigh, following aseptic technique and the specific instructions provided in the product’s prescribing information.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, opportunistic infections due to immune modulation, and rare hematologic abnormalities like neutropenia. Patients should be monitored closely for signs of infection, allergic response, or unexpected laboratory changes during therapy.

Nemluvio is contraindicated in individuals with known hypersensitivity to nemolizumab or any of its excipients. It should also be avoided in patients receiving live vaccines during treatment and in those with active, uncontrolled infections until the infection is resolved.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nemolizumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT